scholarly journals Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome

2013 ◽  
Vol 169 (6) ◽  
pp. 743-749 ◽  
Author(s):  
R Selice ◽  
N Caretta ◽  
A Di Mambro ◽  
M Torino ◽  
P Palego ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Prostate Volume ◽  
Klinefelter Syndrome ◽  
Visceral Obesity ◽  
Reproductive Hormones ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Model Assessment ◽  
Increased Risk

ObjectiveKlinefelter syndrome (KS) is a chromosomal alteration characterized by increased risk of metabolic syndrome, mainly caused by visceral obesity. In the last years, obesity has been studied as a potential risk factor for prostate disease and recently a link has been demonstrated between visceral adiposity with prostate volume. The aim of this study was to analyze the relationship between obesity and prostate volume and growth during testosterone therapy in KS subjects.Design and methodsWe evaluated reproductive hormones, metabolic parameters, anthropometric measures, PSA, and prostate volume in 121 naïve non-mosaic KS patients and 60 age-matched healthy male controls. Fifty-six KS hypogonadic subjects were treated with testosterone-gel 2% and reevaluated after 18 months of treatment.ResultsProstate volume in KS was positively related to waist circumference (WC). The KS group with WC ≥94 cm had significantly higher prostate volume, BMI, insulin plasma levels, homeostasis model assessment index, total cholesterol, triglycerides, and glycemia with respect to the KS group with WC <94 cm. After testosterone replacement therapy, only hypogonadic KS men with WC ≥94 cm had a statistically significant increase in prostate volume. Furthermore, in untreated KS subjects, prostate volume showed a statistically significant increase after 18 months of follow-up only in subjects with WC ≥94 cm.ConclusionsThis study showed that visceral obesity, insulin resistance, and lipid and glucose metabolism alterations are associated with prostate volume and growth during testosterone replacement therapy in KS, independently from androgen or estrogen levels. These latter findings might provide the basis for a better management and follow-up of KS subjects.

Fire Setting and Klinefelter Syndrome

PEDIATRICS ◽  
1989 ◽  
Vol 84 (4) ◽  
pp. 749-749
Author(s):  
STEPHEN G. KALER ◽  
BEVERLY J. WHITE ◽  
MARKUS J.P. KRUESI
Keyword(s):  
Replacement Therapy ◽  
Sex Chromosome ◽  
Klinefelter Syndrome ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Sex Chromosome Aneuploidy ◽  
Chromosome Aneuploidy ◽  
Fire Setting

Miller and Sulkes' recently described an association between XXY sex chromosome aneuploidy (Klinefelter syndrome) and chronic fire-setting behavior. The association was noted in four individuals evaluated by them in Rochester, NY, during a 4-year peroid and was observed in 19% (6 of 31 persons) of XXY individuals reported by others. Following institution of testosterone replacement therapy, the 3 of their patients for whom follow-up was available had no evidence of additional fire-setting behavior.

scholarly journals Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism

2019 ◽  
Vol 188 (9) ◽  
pp. 1666-1673 ◽  
Author(s):  
Christina Santella ◽  
Christel Renoux ◽  
Hui Yin ◽  
Oriana H Y Yu ◽  
Laurent Azoulay
Keyword(s):  
Prostate Cancer ◽  
Replacement Therapy ◽  
Late Onset ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Newly Diagnosed ◽  
Increased Risk ◽  
Late Onset Hypogonadism ◽  
The Impact

Abstract The association between the use of testosterone replacement therapy (TRT) and prostate cancer remains uncertain. Thus, we investigated whether TRT is associated with an increased risk of prostate cancer in men with late-onset hypogonadism. We used the UK Clinical Practice Research Datalink to assemble a cohort of 12,779 men who were newly diagnosed with hypogonadism between January 1, 1995, and August 31, 2016, with follow-up until August 31, 2017. Exposure to TRT was treated as a time-varying variable and lagged by 1 year to account for cancer latency, with nonuse as the reference category. During 58,224 person-years of follow-up, a total of 215 patients were newly diagnosed with prostate cancer, generating an incidence rate of 3.7 per 1,000 person-years. In time-dependent Cox proportional hazards models, use of TRT was not associated with an overall increased risk of prostate cancer (hazard ratio = 0.97; 95% confidence interval: 0.71, 1.32) compared with nonuse. Results remained consistent in secondary and sensitivity analyses, as well as in a propensity score–matched cohort analysis that further assessed the impact of residual confounding. Overall, the use of TRT was not associated with an increased risk of prostate cancer in men with late-onset hypogonadism.

Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome

Endocrine ◽  
2018 ◽  
Vol 61 (2) ◽  
pp. 327-335 ◽  
Author(s):  
N. Tahani ◽  
L. Nieddu ◽  
G. Prossomariti ◽  
M. Spaziani ◽  
S. Granato ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Klinefelter Syndrome ◽  
Term Effect ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Long Term Effect

scholarly journals Evolution of Guidelines for Testosterone Replacement Therapy

2019 ◽  
Vol 8 (3) ◽  
pp. 410 ◽  
Author(s):  
Hyun Park ◽  
Sun Ahn ◽  
Du Moon
Keyword(s):  
Clinical Practice ◽  
Replacement Therapy ◽  
Clinical Symptoms ◽  
Serum Testosterone ◽  
Diagnosis And Treatment ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Testosterone Deficiency ◽  
Developmental Growth

Testosterone is an essential hormone required for the developmental growth and maintenance of the male phenotype during the whole life. With the increasing male life expectancy worldwide and development of adequate testosterone preparations, the prescription of testosterone has increased tremendously. Testosterone replacement should be based on low serum testosterone and related clinical symptoms. In the last two decades, with the accumulation of data, official recommendations have evolved in terms of definition, diagnosis, treatment, and follow-up. In practice, it is better for physicians to follow the Institutional Official Recommendations or Clinical Practice Guideline for an adequate diagnosis and treatment of testosterone deficiency. Currently, four official recommendations are available for diagnosis and treatment of patients with testosterone deficiency. The inconsistencies in the guidelines merely create confusion among the physicians instead of providing clear information. Furthermore, there is no definite method to assess serum testosterone and clinical symptoms. In the era of active testosterone replacement therapy (TRT), physicians’ practice patterns should be consistent with the clinical practice guidelines to avoid the misuse of testosterone. In this review, the author introduces the evolution of clinical guidelines to provide a comprehensive understanding of the differences and controversies with respect to TRT.

scholarly journals Testosterone Replacement Therapy and the Risk of Hypoglycemia

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Analía Verónica Yamaguchi ◽  
Pablo René Costanzo ◽  
Verónica Andrea Peuchot ◽  
Pablo Knoblovits
Keyword(s):  
Type 2 Diabetes ◽  
Drug Interaction ◽  
Replacement Therapy ◽  
Metabolic Control ◽  
Klinefelter Syndrome ◽  
Testosterone Replacement ◽  
Hypoglycemic Agents ◽  
Testosterone Replacement Therapy ◽  
History Of

We report the case of a 45-year-old man with a history of Klinefelter syndrome undergoing testosterone replacement therapy, and with type 2 diabetes treated with metformin with poor metabolic control. When vildagliptin was added to his treatment, he presented hypoglycemia after the testosterone injection. We highlight this not widely reported drug interaction between hypoglycemic agents and testosterone.

EFFECT OF TESTOSTERONE REPLACEMENT THERAPY ON SERUM PSA IN PATIENTS WITH KLINEFELTER SYNDROME

2001 ◽  
Vol 47 (3) ◽  
pp. 173-176 ◽  
Author(s):  
T. Shibasaki ◽  
I. Sasagawa ◽  
Y. Suzuki ◽  
H. Yazawa ◽  
O. Ichiyanagi ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Klinefelter Syndrome ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy
Sign in / Sign up

Export Citation Format

Share Document